文献速递泌尿男性生殖肿瘤

HSD3B1基因多态性与mCRPC患者阿比特龙或恩扎卢胺疗效相关

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
PubMed 文献 · Ann Oncol · 2020-06-20

两项前瞻性队列共547例转移性去势抵抗性前列腺癌患者接受阿比特龙或恩扎卢胺治疗,评估HSD3B1(1245A>C)基因型与疗效的关系。CC基因型占15%,与更差的至进展时间(HR 1.31)和更低的PSA应答率(48% vs 62%/65%)相关,但多因素分析未显示独立预后价值。

要点

  • HSD3B1 CC基因型与更短至进展时间和更低PSA应答率相关
  • 基因型效应在阿比特龙和恩扎卢胺间无显著交互作用
  • CC基因型未提供超越标准临床变量的独立预后信息

核心结论

  • HSD3B1 CC基因型与mCRPC患者接受阿比特龙或恩扎卢胺治疗后的更短TTP和更低PSA应答率相关。
  • 但CC基因型未提供超越标准临床变量的预后信息,可能不适合作为独立生物标志物。

研究设计与样本

  • 研究纳入两项前瞻性队列共547例接受阿比特龙或恩扎卢胺治疗的mCRPC患者。
  • 队列1患者随机接受阿比特龙+泼尼松或恩扎卢胺,队列2由研究者选择任一药物。
  • HSD3B1基因型通过靶向测序和/或TaqMan SNP基因分型确定。

主要发现

  • CC基因型占15%,与更差TTP相关(HR 1.31,95%CI 1.02-1.67,P=0.032)。
  • PSA应答率在CC、AA、AC基因型分别为48%、62%、65%(P=0.019)。
  • TTPP差异无统计学意义(HR 1.28,95%CI 0.99-1.66,P=0.064)。
  • 基因型效应在阿比特龙和恩扎卢胺间无显著交互作用(TTPP P=0.997,TTP P=0.749)。
  • 多因素分析未显示基因型与TTP或TTPP的显著关联。

临床怎么用

  • 目前不建议将HSD3B1基因型作为mCRPC患者选择阿比特龙或恩扎卢胺的独立生物标志物。
  • 需结合标准临床变量综合评估mCRPC患者的预后和治疗选择。

局限性

  • 多因素分析未显示基因型独立预后价值,提示结果可能受混杂因素影响。
  • 研究为前瞻性队列分析,HSD3B1基因型的临床实用性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer. The objective of the study was to determine whether this polymorphism is associated with outcomes for metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. PATIENTS AND METHODS: A total of 547 patients treated with abiraterone or enzalutamide from two prospective cohorts were evaluated. The HSD3B1 genotype was determined by targeted sequencing and/or TaqMan single-nucleotide polymorphism genotyping. In cohort 1, patients were randomized to receive abiraterone + prednisone or enzalutamide. In cohort 2, patients received either agent according to investigator's choice. Prostate-specific antigen (PSA) response rate, time to PSA progression (TTPP), time to progression (TTP) and overall survival were determined. Associations between HSD3B1 genotypes and outcomes were evaluated via univariate Cox regression. Multivariable Cox model was used to determine the independent association of each covariate. RESULTS: The HSD3B1 variant genotype (CC) was present in 15% of patients and was associated with worse TTP [hazard ratio (HR) 1.31, 95% confidence interval (CI) 1.02-1.67, P = 0.032] and PSA response rates (48% for CC versus 62% and 65% for AA and AC, respectively [P = 0.019]), with no significant difference in TTPP (HR 1.28, 95% CI 0.99-1.66, P = 0.064). The effect of genotype was similar for treatment with abiraterone or enzalutamide with a negative test for interaction for TTPP (P = 0.997) and TTP (P = 0.749). Multivariable analysis did not show a significant association between genotype and TTP or TTPP. CONCLUSIONS: The HSD3B1 (CC) genotype was associated with shorter TTP and lower PSA response rate in patients with mCRPC treated with abiraterone or enzalutamide. However, the CC genotype did not provide prognostic information beyond that conferred by standard clinical variables, suggesting that it may not be a suitable stand-alone biomarker in mCRPC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Khalaf DJ, Aragón IM, Annala M, et al. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Ann Oncol. 2020. PMID: 32574722. doi:10.1016/j.annonc.2020.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。